{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:30:52Z","timestamp":1769509852988,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ajpc.2024.100681","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T02:32:44Z","timestamp":1715221964000},"page":"100681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Haptoglobin phenotype and intensive glycemic control for coronary artery disease risk reduction in people with type two diabetes: The Veterans Affairs Diabetes Trial"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3584-2227","authenticated-orcid":false,"given":"Leah E","family":"Cahill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel A","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gideon D","family":"Bahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allie S","family":"Carew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew P","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Sapp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric B","family":"Rimm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Reaven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpc.2024.100681_bib0001","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","year":"2010","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.ajpc.2024.100681_bib0002","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajpc.2024.100681_bib0003","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ajpc.2024.100681_bib0004","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1161\/01.RES.0000251741.65179.56","article-title":"haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo","volume":"99","author":"Asleh","year":"2006","journal-title":"Circ Res"},{"issue":"10","key":"10.1016\/j.ajpc.2024.100681_bib0005","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.2337\/db08-0450","article-title":"Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype","volume":"57","author":"Asleh","year":"2008","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.ajpc.2024.100681_bib0006","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1751-553X.2007.00898.x","article-title":"Haptoglobin: a review of the major allele frequencies worldwide and their association with diseases","volume":"29","author":"Carter","year":"2007","journal-title":"Int J Lab Hematol"},{"issue":"7","key":"10.1016\/j.ajpc.2024.100681_bib0007","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jacc.2012.09.063","article-title":"Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin","volume":"61","author":"Cahill","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.ajpc.2024.100681_bib0008","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.jacc.2015.07.076","article-title":"The risk of coronary heart disease associated with glycosylated hemoglobin of 6.5% or greater is pronounced in the haptoglobin 2-2 genotype","volume":"66","author":"Cahill","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.ajpc.2024.100681_bib0009","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1161\/01.RES.0000076889.23082.F1","article-title":"Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease","volume":"92","author":"Asleh","year":"2003","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.ajpc.2024.100681_bib0010","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1161\/01.RES.0000156653.05853.b9","article-title":"Haptoglobin genotype\u2013 and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo","volume":"96","author":"Asleh","year":"2005","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.ajpc.2024.100681_bib0011","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/ATVBAHA.118.312232","article-title":"Haptoglobin phenotype is associated with high-density lipoprotein-bound hemoglobin content and coronary endothelial dysfunction in patients with mild nonobstructive coronary artery disease","volume":"39","author":"Asleh","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.ajpc.2024.100681_bib0012","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jacc.2019.11.051","article-title":"Haptoglobin phenotype modifies the influence of intensive glycemic control on cardiovascular outcomes","volume":"75","author":"Carew","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.ajpc.2024.100681_bib0013","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S1056-8727(02)00277-5","article-title":"Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2","volume":"17","author":"Abraira","year":"2003","journal-title":"J Diabetes Complications"},{"issue":"8","key":"10.1016\/j.ajpc.2024.100681_bib0014","first-page":"1615","article-title":"An enzyme linked immunosorbent assay (ELISA) for the determination of the human haptoglobin phenotype","volume":"51","author":"Levy","year":"2013","journal-title":"NIH Public Access"},{"issue":"3","key":"10.1016\/j.ajpc.2024.100681_bib0015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2174\/156720208785425675","article-title":"Haptoglobin polymorphism and lacunar stroke","volume":"5","author":"Staals","year":"2008","journal-title":"Curr Neurovasc Res"},{"issue":"5","key":"10.1016\/j.ajpc.2024.100681_bib0016","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/1479164114539713","article-title":"Haptoglobin genotype and cerebrovascular disease incidence in type 1 diabetes","volume":"11","author":"Costacou","year":"2014","journal-title":"Diab Vasc Dis Res"},{"issue":"2","key":"10.1016\/j.ajpc.2024.100681_bib0017","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0022-2836(84)90342-5","article-title":"Structure and assembly of haptoglobin polymers by electron microscopy","volume":"174","author":"Wejman","year":"1984","journal-title":"J Mol Biol"},{"issue":"2","key":"10.1016\/j.ajpc.2024.100681_bib0018","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00592-015-0770-8","article-title":"Effect of vitamin E supplementation on HDL function by haptoglobin genotype in type 1 diabetes: results from the HapE randomized crossover pilot trial","volume":"53","author":"Costacou","year":"2015","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.ajpc.2024.100681_bib0019","unstructured":"National Institutes of Health. NIH Policy and Guidelines on The Inclusion of Women and Minorities as Subjects in Clinical Research [Internet]. Available from: https:\/\/grants.nih.gov\/policy\/inclusion\/women-and-minorities\/guidelines.htm."},{"issue":"7","key":"10.1016\/j.ajpc.2024.100681_bib0020","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jama.2021.13304","article-title":"Updated guidance on the reporting of race and ethnicity in medical and science journals","volume":"326","author":"Flanagin","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ajpc.2024.100681_bib0021","doi-asserted-by":"crossref","DOI":"10.2337\/dc23-0760","article-title":"The relationship between time-varying achieved HbA1c and risk of coronary events depends on haptoglobin phenotype among white and black ACCORD participants","author":"Cahill","year":"2023","journal-title":"Diabetes Care"},{"issue":"13","key":"10.1016\/j.ajpc.2024.100681_bib0022","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1182\/blood.V98.13.3693","article-title":"Structure-function analysis of the antioxidant properties of haptoglobin","volume":"98","author":"Melamed-Frank","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ajpc.2024.100681_bib0023","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1161\/01.RES.0000156653.05853.b9","article-title":"Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo","volume":"96","author":"Asleh","year":"2005","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.ajpc.2024.100681_bib0024","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.atherosclerosis.2006.04.032","article-title":"Haptoglobin genotype modulates the balance of Th1\/Th2 cytokines produced by macrophages exposed to free hemoglobin","volume":"191","author":"Guetta","year":"2007","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.ajpc.2024.100681_bib0025","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1161\/CIRCRESAHA.107.149435","article-title":"Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability","volume":"101","author":"Levy","year":"2007","journal-title":"Circ Res"},{"issue":"10","key":"10.1016\/j.ajpc.2024.100681_bib0026","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/clinchem\/42.10.1589","article-title":"Biological and clinical significance of haptoglobin polymorphism in humans","volume":"42","author":"Langlois","year":"1996","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.ajpc.2024.100681_bib0027","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2337\/dc21-1429","article-title":"Haptoglobin phenotype modifies the effect of fenofibrate on risk of coronary event: ACCORD lipid trial","volume":"45","author":"Warren","year":"2022","journal-title":"Diabetes Care"},{"issue":"19","key":"10.1016\/j.ajpc.2024.100681_bib0028","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030288","article-title":"Relationship between time-varying achieved high-density lipoprotein cholesterol and risk of coronary events depends on haptoglobin phenotype within the ACCORD lipid study","volume":"12","author":"Warren","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ajpc.2024.100681_bib0029","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10557-018-06846-w","article-title":"High-density lipoprotein function and dysfunction in health and disease","volume":"33","author":"Chiesa","year":"2019","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"10.1016\/j.ajpc.2024.100681_bib0030","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.metabol.2014.10.010","article-title":"The effect of intensive glucose lowering therapy among major racial\/ethnic groups in the veterans affairs diabetes trial","volume":"64","author":"Saremi","year":"2015","journal-title":"Metabolism"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667724000497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667724000497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T12:23:57Z","timestamp":1719059037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667724000497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":30,"alternative-id":["S2666667724000497"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2024.100681","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Haptoglobin phenotype and intensive glycemic control for coronary artery disease risk reduction in people with type two diabetes: The Veterans Affairs Diabetes Trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2024.100681","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100681"}}